Yahoo Finance26d
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Basel, February 24, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab-ttwe) in the US.From today, the ...
Mint24d
Sandoz Family to Sell $2.9 Billion Stake in Novartis
(Bloomberg) -- Novartis AG’s Sandoz family is poised to sell a roughly 1.2% stake in the Swiss pharmaceutical group. The Sandoz Family Foundation, through the vehicle Emasan AG, is offering 26.5 ...
Yahoo Finance24d
Sandoz family to get $2.9 billion from offloading part of its Novartis stake
ZURICH (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis, the bookrunner on the deal ...
Pharmabiz24d
Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients
Sandoz, the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva (ustekinumab-ttwe) in the US. From February 24, the medicine is commercially available to patients ...
Reuters25d
Sandoz family foundation offers $3 billion worth of Novartis shares
ZURICH, Feb 25 (Reuters) - Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 ...
pharmaphorum6d
Novartis decides Sandoz' future – and it's a spin-out
After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company. The Swiss pharma group said ...
Reuters24d
Sandoz family to get $2.9 billion from offloading part of its Novartis stake
ZURICH, Feb 26 (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis (NOVN.S), opens new tab ...
pharmaphorum1d
Sandoz separates from Novartis, valued at just over $11bn
Sandoz completed its long-heralded separation from Novartis on schedule this morning, with its shares trading at CHF 24 on the SIX Swiss Exchange. That valued the newly independent company at CHF ...
Wall Street Journal8d
Sandoz Group AG
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Hosted on MSN23d
Man Accidentally Poisons Girlfriend’s Dog After Mixing Up Pet’s Medication with Ambien
Beckey Carstens panicked when she came home and learned that her boyfriend had accidentally given their dog Nellie an Ambien rather than the pet's prescribed medication to treat a urinary tract ...
The Pharma Letter26d
Sandoz launches biosimilar Pyzchiva in USA
Swiss generics and biosimilars major Sandoz (SIX: SDZ) has announced the launch of Pyzchiva (ustekinumab-ttwe) in the USA. From today, the medicine is commercially available to patients across the USA ...